You have been in Rotterdam for 36 hours now. You have heard talks on pharmacovigilance signal synthesis across EMA networks. You have seen poster results from three European cancer registries that share an identical challenge with outcomes they cannot route to each other. You had a hallway conversation with a researcher from a Scandinavian hospital that confirmed what your own institution found si